Replies to post #14310 on Biotech Values

[mejs]

"Our highest priority is demonstrating the -Enormous Potential for EVIZON to be a leading therapy in the rapidly growing AMD market. We look forward to communicating continued progress in our clinical trials during the second half of this year."Roy Levitt

Is that positive PR or what's your agenda ?civic08801

[boscosjs]

GP....whatever your post is meant to be...

...it most certainly is NOT an "Investor Warning"...

Aren't these stocks largely event-driven? Shouldn't we anticipate activity around the time that such events occur????

IMHO....GENR anticipates two types of upcoming events (within the next say 6 months). First, there should be some release of data from trials 208 and 209. Second, there could be a partnership deal relative to completion of the on-going Phase III trials and commercialization. If they occur in that order, and the data from the two Phase II trials looks bad...the 2nd event will likely not occur.

So, if one is trading this stock, is the question not, "when will this event be likely to occur?" Also, what is the likely outcome?

My (back of the envelope) assumption is that a $1.70 stock is not worth shorting. Thus, GENR is either a bullish possibility, or a non-event.

So, if one is bullish on the outcome of 208 and 209, how long should one wait to get in? If one is already in, does it make sense to exist and then attempt to get back in?

Thus, I find the text of your message a rather obvious statement of non-information and the title rather inflamatory.

If you're looking for an exciting stock to day trade.....maybe you should look elsewhere. Frankly, it is amazing that the daily volume of GENR is as high as it is.


from the bozone-layer,

bosco

[GratziPrego]

RE: GENR Genaera Corporation

DewDiligence,

On August 12th, message #14310, was written to provide valuable information and WARNING to investors about the poor outlook for Genaera Stock (GENR). You responded with a warning that it was considered continual BASHING. Based on the recent performance (the stock is now trading at about $1.46/share and was trading at about 1.75 + or -, at the time of the previous posts about GENAERA not being able to maintain a price of $1.90 or higher).

Now, these are just facts that are being stated above, NOT BASHING. Based on this, what is your opinion about GENAERA? Will it REBOUND and BOUNCE to higher price levels or Continue to DROP in VALUE?